MAZE

Maze Therapeutics, Inc. NASDAQ Listed Jan 31, 2025

Healthcare ·Biotechnology ·US · mazetx.com

$25.50

Mkt Cap $1.4B

52w Low $8.24 38.0% of range 52w High $53.65

50d MA $35.78 200d MA $32.21

P/E (TTM) -8.9x

EV/EBITDA -11.5x

P/B 3.3x

Debt/Equity 0.1x

ROE -36.9%

P/FCF -15.8x

RSI (14) —

ATR (14) —

Beta 5.16

50d MA $35.78

200d MA $32.21

Avg Volume 873.0K

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

SIC Code

2836

CIK (SEC)

1842295

Phone

650 850 5070

171 Oyster Point Blvd · South San Francisco, CA 94080 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 25, 2026	BMO	-0.73	-0.65	+11.0%	31.73	-2.0%	-0.1%	-4.2%	-4.5%	+2.9%	-2.7%	—
Nov 6, 2025	BMO	-0.74	-0.66	+10.8%	29.63	+0.8%	-3.5%	+6.6%	+5.8%	+0.9%	-2.2%	—
Aug 12, 2025	BMO	-0.79	-0.77	+2.5%	13.74	+1.9%	-1.0%	-1.8%	+1.1%	-1.1%	+0.7%	—
May 14, 2025	BMO	-0.76	-1.15	-51.3%	9.06	-2.5%	+2.1%	+0.0%	+4.9%	+4.2%	+4.1%	—
Mar 31, 2025	BMO	0.45	-18.32	-4171.1%	11.01	-2.8%	-10.1%	+4.7%	-10.1%	-2.7%	-1.7%	—
Sep 30, 2024	BMO	—	-0.57	—	—	—	—	—	—	—	—	—
Jun 30, 2024	BMO	—	3.18	—	—	—	—	—	—	—	—	—
Mar 31, 2024	BMO	—	-0.74	—	—	—	—	—	—	—	—	—
Dec 31, 2023	BMO	—	-0.61	—	—	—	—	—	—	—	—	—
Sep 30, 2023	BMO	—	-0.57	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 14	Truist	Maintains	Buy → Buy	—	$27.42	$27.66	+0.9%	+0.9%	-3.0%	+0.1%	+4.5%	-4.5%
Mar 31	JP Morgan	Maintains	Overweight → Overweight	—	$29.01	$29.50	+1.7%	+2.9%	-2.7%	-1.2%	+1.0%	-2.3%
Mar 25	BTIG	Maintains	Buy → Buy	—	$49.00	$40.00	-18.4%	-35.2%	-0.1%	-4.2%	-4.5%	+2.9%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$49.00	$40.00	-18.4%	-35.2%	-0.1%	-4.2%	-4.5%	+2.9%
Mar 16	Wedbush	Maintains	Outperform → Outperform	—	$50.21	$50.96	+1.5%	+2.1%	-1.7%	-3.8%	+2.0%	-2.8%
Mar 9	BTIG	Maintains	Buy → Buy	—	$44.83	$44.00	-1.9%	+0.5%	+13.3%	-1.2%	+2.8%	-3.1%
Mar 4	Guggenheim	Maintains	Buy → Buy	—	$44.18	$46.59	+5.5%	+5.2%	-2.5%	-1.0%	+0.5%	+13.3%
Jan 16	BTIG	Maintains	Buy → Buy	—	$39.81	$39.84	+0.1%	+2.4%	+8.8%	-1.4%	+5.7%	-4.2%
Dec 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.27	$37.89	+1.7%	+11.3%	+2.7%	-2.1%	-0.6%	-1.7%
Nov 7	Wedbush	Maintains	Outperform → Outperform	—	$29.63	$29.87	+0.8%	-3.5%	+6.6%	+5.8%	+0.9%	-2.2%
Sep 29	JP Morgan	Maintains	Overweight → Overweight	—	$27.00	$27.05	+0.2%	-6.7%	+2.9%	-0.5%	+2.7%	+2.3%
Sep 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.50	$23.64	+0.6%	-0.1%	-2.3%	+3.2%	+5.1%	+5.2%
Sep 15	Guggenheim	Maintains	Buy → Buy	—	$23.30	$23.33	+0.1%	-0.2%	+0.9%	+0.2%	-0.1%	-2.3%
Sep 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.80	$24.88	+0.3%	-6.0%	-0.2%	+0.9%	+0.2%	-0.1%
Sep 12	BTIG	Maintains	Buy → Buy	—	$24.80	$24.88	+0.3%	-6.0%	-0.2%	+0.9%	+0.2%	-0.1%
Sep 11	BTIG	Maintains	Buy → Buy	—	$16.02	$21.10	+31.7%	+54.8%	-6.0%	-0.2%	+0.9%	+0.2%
Apr 2	Guggenheim	Maintains	Buy → Buy	—	$9.90	$9.90	+0.0%	+4.7%	-10.1%	-2.7%	-1.7%	-15.1%

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
Apr 29, 2026	Dandekar Atul	CSBO	Sell	7,500	$25.37	$190K	10,503	-0.88%	+2.20%

Data updated apr 25, 2026 8:42pm · Source: massive.com